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Podocyte injury and loss critically contribute to the pathogenesis of proteinuric kidney dis-
eases including diabetic nephropathy. Deregulated lipid metabolism with disturbed free
fatty acid (FFA) metabolism is a characteristic of metabolically unhealthy obesity and type
2 diabetes and likely contributes to end-stage kidney disease irrespective of the underly-
ing kidney disease. In the current review, we summarize recent ﬁndings related to FFAs
and altered renal FFA metabolism with a special focus on podocytes. We will outline the
opposing effects of saturated and monounsaturated FFAs and a particular emphasis will
be given to the underlying molecular mechanisms involving insulin resistance and endo-
plasmic reticulum homeostasis. Finally, recent data suggesting a critical role of renal FFA
metabolism to adapt to an altered lipid environment will be discussed.
Keywords: podocyte, diabetic nephropathy, saturated and monounsaturated free fatty acids, lipid metabolism,
lipotoxicity, endoplasmic reticulum stress, b-oxidation
INTRODUCTION
Diabetic nephropathy (DN) is the major cause of end-stage renal
disease, and most affected patients have type 2 diabetes (1, 2).
Injury and loss of the glomerular epithelial cells or podocytes are
critical in the pathogenesis of DN (3–6). Importantly, the epi-
demic of DN and type 2 diabetes parallels the obesity epidemic
(7, 8), which also drives other causes of chronic kidney disease
(CKD) including obesity-related glomerulopathy and secondary
focalsegmentalglomerulosclerosis[reviewedinRef.(9)].Obesity-
relatedglomerulopathyhasbeenfoundtobemoreassociatedwith
Abbreviations: ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein
kinase; ATF6, activating transcription factor 6; Bcl-2, B-cell lymphoma 2; BiP,
heavy chain binding protein; CHOP, C/EBP homologous protein; chREBP,
carbohydrate responsive element-binding protein; CKD, chronic kidney dis-
ease; CPT, carnitine palmitoyltransferase; DAG, diacylglycerol; DGAT, acyl-
CoA:diacylglycerolacyltransferase; DN, diabetic nephropathy; DR5, death receptor
5; ER, endoplasmic reticulum; ERO1, ER oxidoreductase 1; FFA, free fatty acid;
Gadd34, growth arrest and DNA damage-inducible protein 34; IRE1, inositol-
requiring enzyme 1; IRS, insulin receptor substrate; JNK, c-Jun NH2-terminal
kinase; mTORC1, mammalian target of rapamycin complex 1; MUFA, monoun-
saturated fatty acid; PERK, PKR(protein kinase RNA)-like ER kinase; PKC, protein
kinase C; ROS, reactive oxygen species; SCD, stearoyl-CoA desaturase; SFA, satu-
rated fatty acid; SREBP,sterol regulatory element-binding protein; TG,triglyceride;
TRAIL, tumor necrosis factor related apoptosis inducing ligand; UPR, unfolded
protein response; Xbp1, X-box binding protein.
serum triglyceride (TG) levels and ectopic lipid accumulation in
the kidney than with obesity per se (10). Lipid excess and deregu-
latedlipidmetabolisminthekidneyareincreasinglyrecognizedas
pathogenicfactorsnotonlyinthedevelopmentandprogressionof
obesity-related renal disease and DN but they may also contribute
to CKD irrespective of the underlying pathology (9). Excessive
lipid droplets can be found in different renal cell types including
podocytes (9, 11). Accumulation of lipids in non-adipose tissues
can contribute to cellular dysfunction and cell death, a phenom-
enon that is called lipotoxicity. Elevated plasma free fatty acids
(FFAs)anddisturbedFFAmetabolismcriticallycontributetolipo-
toxicity. However, to which extent and how the various FFAs and
theirmetabolitessuchasdiacylglycerols(DAGs)andTGsarepath-
ogenic or are even part of a protective, adaptive process is under
debate. Recent data also indicate that cholesterol accumulation in
podocytes plays a critical pathogenic role in DN and contributes
to lipotoxicity (12).
Thisreviewwillhighlightthepotentialconsequencesof altered
FFA levels and disturbed FFA metabolism with a special focus
on podocytes. If adaptation fails, lipotoxicity with insulin resis-
tanceandendoplasmicreticulum(ER)stressmayultimatelyresult
in podocyte death. Recent advances in the underlying cellular
processes will be summarized and may help to foster further
research to ﬁnd and translate novel therapeutic strategies. In
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addition, a particular emphasis will be laid on discussing cel-
lular adaptive responses, which might be interesting targets in
supporting podocytes dealing with an altered lipid environment.
PLASMA FREE FATTY ACIDS
A main source of lipids is plasma FFAs, which are hydrolyzed and
relieved from adipocyte TG stores and carried by plasma albumin
to provide energy for tissues during fasting (13). In addition,fatty
acids hydrolyzedfrom liver-derivedlow density lipoproteinTG by
lipoprotein lipases are also contributing to the FFA pool in tissues
(14).FFAlevelsareunderlyingdiurnalﬂuctuationswithlowpost-
prandiallevelswheremostFFAsaretakenupbytheadiposetissue
andincreasedlevelsduringstatesof fasting(15).Incontrasttothe
general belief, obesity is not generally associated with increased
fastingFFAlevels,andthisassociationonlyexistsincertaingroups
of obese and type 2 diabetic patients (16). Elevated FFA levels
are associated with and may result from insulin resistance and
increasedlipolysis(15,17–19).Vice versa,insulinresistancecanbe
the result of elevated FFAs (20). In addition, adipocytes of obese
individualscanbecomedefectiveinFFAuptake,whichcontributes
to elevated FFA levels and promotes ectopic fat deposition (21).
This might be of interest as plasma FFA composition partially
reﬂects dietary fatty acid composition (22) and saturated FFAs
(SFAs),andmonounsaturatedFFAs(MUFAs)havedistincteffects
oncellmetabolismandfunction.Inthiscontext,arecentinterven-
tion trial is of interest, which demonstrated that a Mediterranean
diet enriched with extra-virgin olive oil is effective in the primary
prevention of cardiovascular diseases and diabetes (23,24),and it
has been suggested that this beneﬁcial effect at least in part results
from the high content of MUFAs in olive oil (24). Further inter-
ventional studies are warranted to test whether dietary shifting of
the FFA balance toward unsaturated FFAs can prevent and delay
the progression of obesity-related renal diseases and DN.
OPPOSING EFFECTS OF SFAs AND MUFAs
The SFAs,palmitic and stearic acid,together with the MUFA oleic
acid account for 70–80% of plasma FFAs (25, 26). Interestingly,
in most cell types including podocytes mainly SFAs are inducing
lipotoxicity such as insulin resistance and cell death (27, 28). By
contrast, MUFAs can prevent SFA induced lipotoxicity (Table 1),
i.e.,an equimolar combination of palmitic and oleic acid does not
lead to podocytes death (28). Most of the current understand-
ing of the opposing effects has been derived from studies with
hepatocytes, muscle cells, and pancreatic b-cells linking the detri-
mental actions of SFAs to SFA-derived metabolites such as DAGs
and ceramide (29). DAG-mediated activation of protein kinase C
(PKC) d and increased levels of ceramide are associated with the
intrinsic mitochondrial apoptotic pathway, e.g., increased mito-
chondrial membrane permeability and cytochrome c release (30–
32). Cytochrome c release is also observed in palmitic acid treated
podocytes(preliminarydata).Ofnote,somestudiesshowpartially
conﬂictingﬁndingsinthelightof theeffectsof increasedceramide
synthesis, TG accumulation, and b-oxidation with its associated
reactive oxygen species (ROS) (33–36). In human podocytes,
ceramide accumulation has been linked to palmitic acid-induced
insulin resistance (27); however, the ceramide synthase inhibitor
fumonisin B1 is not ameliorating survival of murine podocytes
Table 1 | Beneﬁcial effects of MUFAs on podocytes treated with
palmitic acid.
Action of MUFAs (e.g., oleic acid) in
podocytes treated with palmitic acid
Reference
Cell viability Prevention of podocyte death (28)
ER stress/
UPR
Induction of the adaptive UPR (e.g., BiP) (28)
Prevention of CHOP induction (28)
Insulin
resistance
Improved insulin sensitivity Unpublished
observation
Lipid
metabolism
Increased fatty acid b-oxidation (37)
Reduced accumulation of palmitic acid in
DAG
Figure 1A
(37)
Preferential incorporation of palmitic acid
intoTG
Figure 1A
(37)
Increased DGAT gene expression Unpublished
observation
Reduced accumulation of palmitic acid
derived metabolites in the total lipid fraction
Figure 1B
(37)
exposed to palmitic acid (37). Of note, tracing studies with
tritium-labeledpalmiticacidcouldshowthatMUFAs,suchasoleic
acid, slightly but signiﬁcantly reduce the total amount of intra-
cellular [3H]palmitic acid containing DAG and TG (Figure 1A).
Moreimportantly,oleicacidleadstopreferentialincorporationof
[3H]palmitic acid derived metabolites into TGs, which is accom-
panied by a reduction of the [H3]palmitic acid containing DAG
fraction [Figure 1A, adapted from Sieber et al. (37)]. Further-
more, oleic acid stimulates b-oxidation of palmitic acid (37) and
maybebeneﬁcialsimplybyreducingthelevelsofpalmiticacidand
its toxic metabolites (38), which might be reﬂected by the overall
decreasedrecoveryoftritiumderivedfromlabeledpalmiticacidin
the total cellular lipid fraction (Figure1B). In summary,although
the beneﬁcial effects of MUFAs are not completely understood,
recent work including studies in podocytes points toward facili-
tated incorporation of palmitic and its metabolites into TGs and
increasedpalmiticacidb-oxidation,whichhavebeenpostulatedto
prevent from accumulation of toxic SFA metabolites (29, 35, 37).
INSULIN RESISTANCE
Inhuman(27)andmurine(preliminarydata)podocytes,palmitic
acid induces insulin resistance. Studies in hepatocytes and skele-
tal muscle cells linked palmitic acid-induced insulin resistance
to alternate serine/threonine phosphorylation of insulin recep-
tor substrate (IRS) 1, 2, and AKT by either ROS-mediated JNK
(c-Jun NH2-terminal kinase) activation or by DAG activation of
PKC (39–41). In podocytes, insulin signaling could be amelio-
rated by JNK inhibition (preliminary data). However,this was not
sufﬁcient to ameliorate survival of podocytes chronically exposed
to palmitic acid (preliminary data). Of note, JNK activation is
also downstream of disturbed ER homeostasis referred to as ER
stress, which has been causatively linked to palmitic acid-induced
podocyte death (28) (see below). Reduced insulin sensitivity is
observed in glomeruli of obese and diabetic rats (42) and normal
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FIGURE 1 | (A)Tracing studies with tritium-labeled palmitic acid reveal that
MUFAs such as oleic acid slightly reduce the total amount of [
3H]palmitic
acid containing DAGCTG in the cellular lipid fraction. In addition, oleic acid
leads to a preferential incorporation of [
3H]palmitic acid intoTG vs. DAG.
(B)Total amount of tritium-labeled metabolites recovered in the total
cellular lipid fraction was decreased in the presence of oleic acid. Adapted
from Sieber et al. (37). nD9; *p <0.01, **p <0.00001.
insulin signalingseems criticalfor podocyte functionand survival
aspodocyte-speciﬁcinsulinreceptorknockoutmicedevelopalbu-
minuria and glomerulosclerosis (43). In summary, these ﬁndings
pointtowardapotentialFFA-mediatedroleof insulinresistancein
the development and progression of obesity-related renal disease
and DN.
ER STRESS
FFA mediated ER stress has been associated with the pathogene-
sis of obesity and type 2 diabetes where it is extensively studied
in the light of pancreatic b-cell failure and the onset of type 2
diabetes (44, 45). ER stress is also observed in the tubulointersti-
tial and glomerular compartment of renal biopsies obtained from
patients with DN (28,46,47). Importantly,ameliorating ER stress
hasbeenshowntoattenuateDNinatype1diabetesmousemodel
(48, 49).
Disturbed ER homeostasis decreases the ER folding capacity
andtherebyleadstoaccumulationof unfoldedandmisfoldedpro-
teins,whichinturninitiatestheunfoldedproteinresponse(UPR).
The UPR is primarily an adaptive response to maintain proper ER
function (50, 51) and involves three signaling branches that are
mediated by the ER transmembrane receptors PERK (PKR-like
ER kinase), ATF6 (activating transcription factor 6), and IRE-1
(inositol-requiring enzyme 1), which ultimately lead to transla-
tional attenuation, ER-associated protein degradation, increased
ER chaperone expression, and ER membrane synthesis. If ER
stress persists, cells initiate apoptosis, which has been linked to
the proapoptotic transcription factor C/EBP homologous protein
(CHOP) (52–55). In podocytes, palmitic acid-induced ER stress
results in the induction of several UPR markers/effectors, includ-
ing the ER chaperone heavy chain binding protein (BiP), Gadd34
(Growth arrest and DNA damage-inducible protein), as well as
alternatesplicingof X-boxbindingprotein1(Xbp1),andupregu-
lation of CHOP [(28) and unpublished results]. Contrariwise,the
monounsaturated palmitoleic and oleic acids alone upregulated
BiP but not CHOP (28).As BiP is known to protect from palmitic
acid-inducedapoptosis(56),theupregulationoftheERchaperone
BiPbyMUFAslikelycontributestotheirbeneﬁcialeffect.Further-
more, MUFAs attenuate palmitic acid-induced upregulation of
CHOPin podocytes,andgene silencingof CHOPprotects against
palmiticacid-inducedpodocytedeath,whichpointstoacausative
role for CHOP (28). A recent study suggests that the detrimental
effects of SFAs are linked to activation of mTORC1 (mammalian
target of rapamycin complex 1) and subsequent CHOP upregula-
tion(57).Similarly,CHOPdeﬁcientmiceareprotectedfromDNas
wellasage-relatedalbuminuria(58).Surprisingly,however,CHOP
levels were either unchanged or signiﬁcantly downregulated in
the tubulointerstitial (46) and glomerular (28) compartment of
renal biopsies obtained from patients with DN,which could indi-
cate that CHOP positive cells may die and be removed from the
tissue. An alternative explanation might be that during the pro-
gression of DN, there is a selection of podocytes adapted to the
alteredenvironment.TheapoptoticactionsofCHOParenotcom-
pletely understood (59); however, proapoptotic targets include
GADD34 (60), DR5 (TRAIL Receptor-2) (61), and ERO1a (ER
oxidoreductase-1a) (62). In addition, CHOP has been associated
with downregulation of anti-apoptotic Bcl-2 (63).
Saturated FFA-mediated ER stress and subsequent UPR have
been associated with altered ER membrane composition and
disrupted ER integrity (64). In addition of being activated by
unfolded proteins, the ER stress sensor IRE-1 has been shown
to be sensitive to alterations in ER membrane lipid composition
(65). This is as in b-cells, palmitic acid-induced ER stress does
notcorrelatewithunfoldedproteins(66).Interestingly,inprelim-
inary experiments, speciﬁc IRE-1 inhibition with the small mole-
cule compound 4m8C attenuates palmitic acid-induced podocyte
death, which is in accordance with the crucial role of IRE-1 in
determining cell fate (67, 68).
CELLULAR ADAPTIVE RESPONSES: REGULATION OF
b-OXIDATION
SFA lipotoxicity has been linked to lipid accumulation includ-
ing TGs (69, 70) and increased ROS derived from enhanced
b-oxidation (39). However,recent ﬁndings indicate that increased
FFAb-oxidationaswellasTGsynthesismaynothavetobeharmful
in any case,but may reﬂect a protective adaptive response helping
podocytes to deal with elevated FFA levels.
Speciﬁcally, increasing fatty acid oxidation reduces the suscep-
tibility of podocytes to palmitic acid (38). Fatty acid b-oxidation
can be enhanced by AICAR (5-Aminoimidazole-4-carboxamide
ribonucleotide), an agonist of the energy-sensor AMPK (AMP-
activated protein kinase), which inactivates the acetyl-CoA car-
boxylase(ACC)andtherebyreduceslevelsof thenaturalcarnitine
palmitoyltransferase 1 (CPT1) inhibitor malonyl-CoA. The pro-
tectiveeffectofAicaronpalmiticacidcouldbereversedbyinhibit-
ingCPT1,therate-limitingenzymeoffattyacidb-oxidation.Simi-
larly,ACC-silencedpodocyteswerelesssusceptibletopalmiticacid
(38). Importantly,several recent genome-wide association studies
in type 2 diabetic patients found a single-nucleotide polymor-
phism in a non-coding region of ACC2 to be strongly associated
with proteinuria (71–73). The polymorphism is associated with
increased ACC2 expression (71), which tends to increased levels
of the CPT1 inhibitor malonyl-CoA and diminished fatty acid
b-oxidation capacity.
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Of interest, the adipocyte-derived hormone adiponectin, a
physiological activator of AMPK signaling, slightly improves sur-
vival of podocytes treated with palmitic acid (38). However, the
protective effect could only be seen in the presence of high glu-
cose, which is known to reduce AMPK signaling (74) and thereby
allowed to uncover the effect of adiponectin (38). This observa-
tion is in line with and gives a further explanation for the known
renoprotective effect of adiponectin (74).
A recent study found an altered gene expression proﬁle of key
enzymes of fatty acid metabolism in glomeruli of patients with
DN (37). Of note, an upregulation of all three CPT1 isoforms
and a downregulation of ACC2 were found (37), which both sug-
gest disposition for increased fatty oxidation. An increase in fatty
acid oxidation likely contributes to a protective,adaptive response
by decreasing the load of toxic SFAs (38). A second study, how-
ever,found a decreased expression of CPT1 in DN (11). However,
these results were obtained from whole kidneys (11) and not from
glomerular extracts (37), which may explain these discrepancies.
CELLULAR ADAPTIVE RESPONSES: SCD1 EXPRESSION AND
REGULATION OF TG SYNTHESIS
Bothaforementionedgeneexpressionanalysesfoundanincreased
expression of stearoyl-CoA desaturases (SCD) 1 in diabetic
kidneys (11, 37) and by immunohistochemistry the glomerular
upregulation of SCD1 could be mainly localized to podocytes
(37). SCDs desaturate SFAs to MUFAs and thereby provide acyl-
CoA:diacylglycerolacyltransferases (DGATs), which catalyze the
ﬁnal step in TG synthesis, with their preferred substrates (75,
76). In glomeruli, the expression of DGAT1 was also found to be
increased (37), and together these results indicate not only facili-
tated conversion of toxic SFAs to MUFAs but also stimulation of
TG synthesis.
In obesity, accumulation of TG has been linked to peripheral
lipotoxicity(69,70);however,TGstoragemightnotbepathogenic
per se as endurance-trained athletes show higher TG levels as well
as higher insulin sensitivity in skeletal muscle, a phenomenon
known as the “athletes’ paradox” (77, 78). Also, transgenic mice
overexpressing the TG-synthesizing enzyme DGAT1 in the heart
haveanincreasedTGcontent,butimprovedcardiacfunction(79).
Moreover, mice overexpressing chREBP (carbohydrate response
element-bindingprotein)fedahigh-fatdiethaveincreasedhepatic
levels of SCD1 and DGAT1 and show elevated insulin sensitiv-
ity despite increased hepatic steatosis (80). On the other hand,
at some point, renal lipid accumulation may become harmful
and a reduction in lipid overload by farnesoid X receptor ago-
nists, which reduce the lipid synthesis regulator SREBP-1 (sterol
FIGURE 2 |Working model for increased plasma FFA levels and/or a
shift toward SFAs on podocytes. In obesity and type 2 diabetes,
increased adipose tissue lipolysis and/or a FFA uptake defect of adipocytes
together with increased dietary FFA intake results in elevated plasma FFAs
and a “spillover” of FFAs to non-adipose tissues including the kidney and
podocytes. Podocytes may adapt to the altered lipid environment by
upregulating fatty acid b-oxidation,TG synthesis, and the adaptive branch
of the UPR. However, impaired adaptive capacity (e.g., genetic) or chronic
“overload” leading to accumulation of toxic FFA metabolites and/or
excessiveTG storage may lead to diminished podocyte function and
ultimately podocyte death resulting in obesity-related glomerulopathy
and DN.
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regulatory element-binding protein), has been shown to slow the
progression of DN (81) and obesity-induced nephropathy (82). It
can be hypothesized that the extent, location, and context of TG
deposition determine lipotoxicity, and speciﬁcally, if it prevents
accumulationofevenmoretoxicSFAmetabolitessuchasceramide
and DAGs, the beneﬁcial effects may outweigh [Figure 2 (35)].
Pharmacological stimulation of SCDs by liver X receptor ago-
nists protects podocytes from palmitic acid-induced cell death
and this protective effect is lost in podocytes deﬁcient of SCD1
and 2.Also,SCD1 and 2 double deﬁcient podocytes are more sus-
ceptible to palmitic acid, but genetic overexpression of SCD1 is
protective. These data suggest that the abovementioned increased
expression of SCD1 in podocytes likely is part of a protective,
adaptive response, which helps podocytes dealing with FFAs.
SUMMARY AND CONCLUSION
Disorderedlipidmetabolismandrenallipidaccumulationarenot
onlyassociatedwithobesity-relatedrenaldiseaseandDNbutthere
is also growing insight that they contribute to the disease process.
Recent human and experimental studies suggest that disturbed
FFA metabolism plays a critical role in disordered lipid metabo-
lism.As podocytes are highly susceptible to the saturated palmitic
acid, but protected by MUFAs as well as increased expression of
SCDs, the upregulation of SCD1 in podocytes of diabetic kid-
neys likely is part of a protective mechanism against SFAs and
their toxic metabolites. The toxicity of SFAs in podocytes is par-
tially explained by induction of ER stress and insulin resistance.
Several mechanisms can explain the protective effect of MUFAs
in podocytes including attenuation of the palmitic acid-induced
CHOP upregulation and stimulation of fatty acid b-oxidation.
The potentially crucial importance of b-oxidation is supported by
genome-wideassociationstudiesintype2diabeticpatients,which
found that a single-nucleotide polymorphism in ACC2 favoring
impairment of b-oxidation is associated with proteinuria. The
observationthattheprotectiveeffectofMUFAsisassociatedwitha
shiftofpalmiticacidfromDAGtoTGsuggeststhat“limited”accu-
mulation of TGs in podocytes does not have to be deleterious,but
maypreventaccumulationof evenmoretoxicFFAmetabolites.In
conclusion,recent data not only suggest that podocytes are highly
susceptible to FFAs, but they have also the potential to adapt to a
certain extent to an altered lipid environment (Figure 2). In light
of these ﬁndings, obese or type 2 diabetic patients with reduced
ability for an adaptive response to a disturbed lipid metabolism
are likely more prone to develop proteinuria and CKD (Figure2).
Therefore,novel strategies supporting podocytes in their adaptive
responses may help to prevent and delay progression of CKD.
ACKNOWLEDGMENTS
Jonas Sieber is supported by a Swiss Foundation for Grants in
Biology and Medicine Fellowship (P3SMP3_151739/1). Andreas
Werner Jehle is supported by Swiss National Science Founda-
tion grants (31003A-119974 and 31003A-144112/1), by the Swiss
Diabetes Foundation, and by Fondation Sana, Switzerland.
REFERENCES
1. USRDS:the United States renal data system.Am J Kidney Dis (2003) 42(6 Suppl
5):1–230.
2. Locatelli F,Pozzoni P,DelVecchio L. Renal replacement therapy in patients with
diabetesandend-stagerenaldisease.JAmSocNephrol (2004)15(Suppl1):S25–9.
doi:10.1097/01.ASN.0000093239.32602.04
3. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P. Is
podocyte injury relevant in diabetic nephropathy? Studies in patients with type
2 diabetes. Diabetes (2003) 52(4):1031–5. doi:10.2337/diabetes.52.4.1031
4. PagtalunanME,MillerPL,Jumping-EagleS,NelsonRG,MyersBD,RennkeHG,
et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin
Invest (1997) 99(2):342–8. doi:10.1172/JCI119163
5. White KE, Bilous RW; Diabiopsies Study Group. Structural alterations to the
podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial
Transplant (2004) 19(6):1437–40. doi:10.1093/ndt/gfh129
6. ChenHM,LiuZH,ZengCH,LiSJ,WangQW,LiLS.Podocytelesionsinpatients
with obesity-related glomerulopathy. Am J Kidney Dis (2006) 48(5):772–9.
doi:10.1053/j.ajkd.2006.04.079
7. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence
of chronic kidney disease in the United States. JAMA (2007) 298(17):2038–47.
doi:10.1001/jama.298.17.2038
8. Eckardt KU,Coresh J,Devuyst O,Johnson RJ,KöttgenA,LeveyAS,et al. Evolv-
ing importance of kidney disease: from subspecialty to global health burden.
Lancet (2013) 382(9887):158–69. doi:10.1016/S0140-6736(13)60439-0
9. de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al.
Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease.
Lancet Diabetes Endocrinol (2014) 2(5):417–26. doi:10.1016/S2213-8587(14)
70065-8
10. Verani RR. Obesity-associated focal segmental glomerulosclerosis: pathological
features of the lesion and relationship with cardiomegaly and hyperlipidemia.
Am J Kidney Dis (1992) 20(6):629–34. doi:10.1016/S0272-6386(12)70230-5
11. Herman-Edelstein M, Scherzer P, Tobar A, Levi M, Gafter U. Altered renal
lipid metabolism and renal lipid accumulation in human diabetic nephropathy.
J Lipid Res (2014) 55(3):561–72. doi:10.1194/jlr.P040501
12. Merscher-Gomez S,Guzman J,Pedigo CE,Lehto M,Aguillon-Prada R,Mendez
A, et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes
(2013) 62(11):3817–27. doi:10.2337/db13-0399
13. LafontanM,LanginD.Lipolysisandlipidmobilizationinhumanadiposetissue.
Prog Lipid Res (2009) 48(5):275–97. doi:10.1016/j.plipres.2009.05.001
14. Teusink B, Voshol PJ, Dahlmans VE, Rensen PC, Pijl H, Romijn JA, et al. Con-
tribution of fatty acids released from lipolysis of plasma triglycerides to total
plasma fatty acid ﬂux and tissue-speciﬁc fatty acid uptake. Diabetes (2003)
52(3):614–20. doi:10.2337/diabetes.52.3.614
15. Reaven GM,Hollenbeck C,Jeng CY,Wu MS,ChenYD. Measurement of plasma
glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM.
Diabetes (1988) 37(8):1020–4. doi:10.2337/diabetes.37.1.28
16. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance:
timeforareevaluation.Diabetes (2011)60(10):2441–9.doi:10.2337/db11-0425
17. Engfeldt P, Arner P. Lipolysis in human adipocytes, effects of cell size, age and
of regional differences. Horm Metab Res Suppl (1988) 19:26–9.
18. Lionetti L, Mollica MP, Lombardi A, Cavaliere G, Gifuni G, Barletta A. From
chronic overnutrition to insulin resistance: the role of fat-storing capacity and
inﬂammation. Nutr Metab Cardiovasc Dis (2009) 19(2):146–52. doi:10.1016/j.
numecd.2008.10.010
19. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet (2005)
365(9468):1415–28. doi:10.1016/S0140-6736(05)66378-7
20. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al.
Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest
(1996) 97(12):2859–65. doi:10.1172/JCI118742
21. McQuaid SE, Hodson L, Neville MJ, Dennis AL, Cheeseman J, Humphreys SM,
et al. Downregulation of adipose tissue fatty acid trafﬁcking in obesity: a driver
forectopicfatdeposition?Diabetes (2011)60(1):47–55.doi:10.2337/db10-0867
22. Fielding BA,Callow J,Owen RM,Samra JS,Matthews DR,Frayn KN. Postpran-
dial lipemia: the origin of an early peak studied by speciﬁc dietary fatty acid
intake during sequential meals. Am J Clin Nutr (1996) 63(1):36–41.
23. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary
prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med
(2013) 368(14):1279–90. doi:10.1056/NEJMoa1200303
24. Salas-Salvadó J, Bulló M, Estruch R, Ros E, Covas MI, Ibarrola-Jurado N, et al.
Prevention of diabetes with Mediterranean diets: a subgroup analysis of a ran-
domized trial. Ann Intern Med (2014) 160(1):1–10. doi:10.7326/m13-1725
www.frontiersin.org October 2014 | Volume 5 | Article 186 | 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sieber and Jehle FFAs affect podocyte function
25. Hagenfeldt L, Wahren J, Pernow B, Räf L. Uptake of individual free fatty
acids by skeletal muscle and liver in man. J Clin Invest (1972) 51(9):2324–30.
doi:10.1172/JCI107043
26. Raclot T, Langin D, Lafontan M, Groscolas R. Selective release of human
adipocytefattyacidsaccordingtomolecularstructure.BiochemJ (1997)324(Pt
3):911–5.
27. Lennon R, Pons D, Sabin MA, Wei C, Shield JP, Coward RJ, et al. Satu-
rated fatty acids induce insulin resistance in human podocytes: implications
for diabetic nephropathy. Nephrol Dial Transplant (2009) 24(11):3288–96.
doi:10.1093/ndt/gfp302
28. Sieber J,Lindenmeyer MT,Kampe K,Campbell KN,Cohen CD,Hopfer H,et al.
Regulationof podocytesurvivalandendoplasmicreticulumstressbyfattyacids.
Am J Physiol Renal Physiol (2010) 299(4):F821–9. doi:10.1152/ajprenal.00196.
2010
29. Prentki M, Madiraju SR. Glycerolipid metabolism and signaling in health and
disease. Endocr Rev (2008) 29(6):647–76. doi:10.1210/er.2008-0007
30. Novgorodov SA, Szulc ZM, Luberto C, Jones JA, Bielawski J, Bielawska A, et al.
Positively charged ceramide is a potent inducer of mitochondrial permeabiliza-
tion. J Biol Chem (2005) 280(16):16096–105. doi:10.1074/jbc.M411707200
31. Galadari S, Rahman A, Pallichankandy S, Galadari A, Thayyullathil F. Role of
ceramide in diabetes mellitus: evidence and mechanisms. Lipids Health Dis
(2013) 12:98. doi:10.1186/1476-511X-12-98
32. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors
in cancer. Nat Rev Cancer (2007) 7(4):281–94. doi:10.1038/nrc2110
33. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY. Distinct
effects of saturated and monounsaturated fatty acids on beta-cell turnover and
function. Diabetes (2001) 50(1):69–76. doi:10.2337/diabetes.50.1.69
34. Listenberger LL, Ory DS, Schaffer JE. Palmitate-induced apoptosis can occur
throughaceramide-independentpathway.JBiolChem(2001)276(18):14890–5.
doi:10.1074/jbc.M010286200
35. Nolan CJ, Larter CZ. Lipotoxicity: why do saturated fatty acids cause and
monounsaturatesprotectagainstit?JGastroenterolHepatol (2009)24(5):703–6.
doi:10.1111/j.1440-1746.2009.05823.x
36. Baldwin AC, Green CD, Olson LK, Moxley MA, Corbett JA. A role for aber-
rant protein palmitoylation in FFA-induced ER stress and b-cell death. Am
J Physiol Endocrinol Metab (2012) 302(11):E1390–8. doi:10.1152/ajpendo.
00519.2011
37. Sieber J, Weins A, Kampe K, Gruber S, Lindenmeyer MT, Cohen CD, et al.
Susceptibility of podocytes to palmitic acid is regulated by stearoyl-CoA
desaturases 1 and 2. Am J Pathol (2013) 183(3):735–44. doi:10.1016/j.ajpath.
2013.05.023
38. KampeK,SieberJ,OrellanaJM,MundelP,JehleAW.Susceptibilityof podocytes
to palmitic acid is regulated by fatty acid oxidation and inversely depends
on acetyl-CoA carboxylases 1 and 2. Am J Physiol Renal Physiol (2014)
306(4):F401–9. doi:10.1152/ajprenal.00454.2013
39. Nakamura S, Takamura T, Matsuzawa-Nagata N, Takayama H, Misu H,
Noda H, et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes
through reactive oxygen species produced by mitochondria. J Biol Chem (2009)
284(22):14809–18. doi:10.1074/jbc.M901488200
40. Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit
induction of insulin gene transcription by JNK-mediated phosphorylation of
insulin-receptor substrates. Proc Natl Acad Sci U S A (2006) 103(44):16454–9.
doi:10.1073/pnas.0607626103
41. Turban S, Hajduch E. Protein kinase C isoforms: mediators of reactive
lipid metabolites in the development of insulin resistance. FEBS Lett (2011)
585(2):269–74. doi:10.1016/j.febslet.2010.12.022
42. MimaA,OhshiroY,KitadaM,MatsumotoM,GeraldesP,LiC,et al.Glomerular-
speciﬁc protein kinase C-b-induced insulin receptor substrate-1 dysfunction
and insulin resistance in rat models of diabetes and obesity. Kidney Int (2011)
79(8):883–96. doi:10.1038/ki.2010.526
43. Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, et al. Insulin
signaling to the glomerular podocyte is critical for normal kidney function. Cell
Metab (2010) 12(4):329–40. doi:10.1016/j.cmet.2010.08.015
44. Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes.
Annu Rev Biochem (2012) 81:767–93. doi:10.1146/annurev-biochem-072909-
095555
45. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al.
Chemical chaperones reduce ER stress and restore glucose homeostasis in a
mouse model of type 2 diabetes. Science (2006) 313(5790):1137–40. doi:10.
1126/science.1128294
46. Lindenmeyer MT,Rastaldi MP,Ikehata M,Neusser MA,Kretzler M,Cohen CD,
et al. Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J Am
Soc Nephrol (2008) 19(11):2225–36. doi:10.1681/ASN.2007121313
47. Cunard R, Sharma K. The endoplasmic reticulum stress response and dia-
betic kidney disease. Am J Physiol Renal Physiol (2011) 300(5):F1054–61.
doi:10.1152/ajprenal.00021.2011
48. Luo ZF, Feng B, Mu J, Qi W, Zeng W, Guo YH, et al. Effects of 4-phenylbutyric
acidontheprocessanddevelopmentof diabeticnephropathyinducedinratsby
streptozotocin:regulation of endoplasmic reticulum stress-oxidative activation.
Toxicol Appl Pharmacol (2010) 246(1–2):49–57. doi:10.1016/j.taap.2010.04.005
49. Qi W, Mu J, Luo ZF, Zeng W, Guo YH, Pang Q, et al. Attenuation of dia-
betic nephropathy in diabetes rats induced by streptozotocin by regulating
the endoplasmic reticulum stress inﬂammatory response. Metabolism (2011)
60(5):594–603. doi:10.1016/j.metabol.2010.07.021
50. KaufmanRJ.Orchestratingtheunfoldedproteinresponseinhealthanddisease.
J Clin Invest (2002) 110(10):1389–98. doi:10.1172/JCI200216886
51. MaY,HendershotLM.Theunfoldingtaleof theunfoldedproteinresponse.Cell
(2001) 107(7):827–30. doi:10.1016/S0092-8674(01)00623-7
52. Rasheva VI, Domingos PM. Cellular responses to endoplasmic reticulum
stress and apoptosis. Apoptosis (2009) 14(8):996–1007. doi:10.1007/s10495-
009-0341-y
53. Travers KJ,Patil CK,Wodicka L,LockhartDJ,WeissmanJS,WalterP. Functional
and genomic analyses reveal an essential coordination between the unfolded
protein response and ER-associated degradation. Cell (2000) 101(3):249–58.
doi:10.1016/S0092-8674(00)80835-1
54. Lee AH, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic
reticulum resident chaperone genes in the unfolded protein response. Mol Cell
Biol (2003) 23(21):7448–59. doi:10.1128/MCB.23.23.8913-8923.2003
55. Acosta-Alvear D, Zhou Y, Blais A, Tsikitis M, Lents NH, Arias C, et al. XBP1
controlsdiversecelltype-andcondition-speciﬁctranscriptionalregulatorynet-
works. Mol Cell (2007) 27(1):53–66. doi:10.1016/j.molcel.2007.06.011
56. Laybutt DR,Preston AM,Akerfeldt MC,Kench JG,Busch AK,Biankin AV,et al.
Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 dia-
betes. Diabetologia (2007) 50(4):752–63. doi:10.1007/s00125-007-0749-2
57. Yasuda M, Tanaka Y, Kume S, Morita Y, Chin-Kanasaki M, Araki H, et al. Fatty
acids are novel nutrient factors to regulate mTORC1 lysosomal localization
and apoptosis in podocytes. Biochim Biophys Acta (2014) 1842(7):1097–108.
doi:10.1016/j.bbadis.2014.04.001
58. Wu J, Zhang R, Torreggiani M, Ting A, Xiong H, Striker GE, et al. Induction of
diabetes in aged C57B6 mice results in severe nephropathy: an association with
oxidative stress, endoplasmic reticulum stress, and inﬂammation. Am J Pathol
(2010) 176(5):2163–76. doi:10.2353/ajpath.2010.090386
59. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum
stress. Cell Death Differ (2004) 11(4):381–9. doi:10.1038/sj.cdd.4401373
60. Marciniak SJ,Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, et al. CHOP
induces death by promoting protein synthesis and oxidation in the stressed
endoplasmic reticulum. Genes Dev (2004) 18(24):3066–77. doi:10.1101/gad.
1250704
61. Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-
induced apoptosis by enhancing DR5 expression in human carcinoma cells.
J Biol Chem (2004) 279(44):45495–502. doi:10.1074/jbc.M406933200
62. Li G, Mongillo M, Chin KT, Harding H, Ron D, Marks AR, et al. Role of
ERO1-alpha-mediatedstimulationof inositol1,4,5-triphosphatereceptoractiv-
ity in endoplasmic reticulum stress-induced apoptosis. J Cell Biol (2009)
186(6):783–92. doi:10.1083/jcb.200904060
63. McCullough KD, Martindale JL, Klotz LO, Aw TY, Holbrook NJ. Gadd153 sen-
sitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and per-
turbingthecellularredoxstate.MolCellBiol (2001)21(4):1249–59.doi:10.1128/
MCB.21.4.1249-1259.2001
64. Borradaile NM, Han X, Harp JD, Gale SE, Ory DS, Schaffer JE. Disruption of
endoplasmicreticulumstructureandintegrityinlipotoxiccelldeath.JLipidRes
(2006) 47(12):2726–37. doi:10.1194/jlr.M600299-JLR200
65. Promlek T, Ishiwata-Kimata Y, Shido M, Sakuramoto M, Kohno K, Kimata Y.
Membrane aberrancy and unfolded proteins activate the endoplasmic reticu-
lum stress sensor Ire1 in different ways. Mol Biol Cell (2011) 22(18):3520–32.
doi:10.1091/mbc.E11-04-0295
66. Preston AM, Gurisik E, Bartley C, Laybutt DR, Biden TJ. Reduced endoplas-
mic reticulum (ER)-to-Golgi protein trafﬁcking contributes to ER stress in
lipotoxic mouse beta cells by promoting protein overload. Diabetologia (2009)
52(11):2369–73. doi:10.1007/s00125-009-1506-5
Frontiers in Endocrinology | Cellular Endocrinology October 2014 | Volume 5 | Article 186 | 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sieber and Jehle FFAs affect podocyte function
67. Maurel M, Chevet E, Tavernier J, Gerlo S. Getting RIDD of RNA: IRE1 in cell
fateregulation.TrendsBiochemSci (2014)39(5):245–54.doi:10.1016/j.tibs.2014.
02.008
68. Chen Y, Brandizzi F. IRE1: ER stress sensor and cell fate executor. Trends Cell
Biol (2013) 23(11):547–55. doi:10.1016/j.tcb.2013.06.005
69. GuoZK,JensenMD.Acceleratedintramyocellulartriglyceridesynthesisinskele-
tal muscle of high-fat-induced obese rats. Int J Obes Relat Metab Disord (2003)
27(9):1014–9. doi:10.1038/sj.ijo.0802380
70. Zhang XJ, Chinkes DL, Wu Z, Herndon DN, Wolfe RR. The synthetic rate of
muscle triglyceride but not phospholipid is increased in obese rabbits. Metabo-
lism (2009) 58(11):1649–56. doi:10.1016/j.metabol.2009.05.021
71. Maeda S,Kobayashi MA,Araki S,Babazono T,Freedman BI,Bostrom MA,et al.
A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase
beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS
Genet (2010) 6(2):e1000842. doi:10.1371/journal.pgen.1000842
72. Tang SC, Leung VT, Chan LY, Wong SS, Chu DW, Leung JC, et al. The acetyl-
coenzyme A carboxylase beta (ACACB) gene is associated with nephropa-
thy in Chinese patients with type 2 diabetes. Nephrol Dial Transplant (2010)
25(12):3931–4. doi:10.1093/ndt/gfq303
73. Shah VN, Cheema BS, Sharma R, Khullar M, Kohli HS, Ahluwalia TS, et al.
ACACbeta gene (rs2268388) and AGTR1 gene (rs5186) polymorphism and the
risk of nephropathy in Asian Indian patients with type 2 diabetes. Mol Cell
Biochem (2013) 372(1–2):191–8. doi:10.1007/s11010-012-1460-2
74. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, et al.
Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest
(2008) 118(5):1645–56. doi:10.1172/JCI32691
75. Listenberger LL,Han X,Lewis SE,Cases S,Farese RV,Ory DS,et al. Triglyceride
accumulationprotectsagainstfattyacid-inducedlipotoxicity.ProcNatlAcadSci
U S A (2003) 100(6):3077–82. doi:10.1073/pnas.0630588100
76. YenCL,StoneSJ,KoliwadS,HarrisC,FareseRVJr.Thematicreviewseries:glyc-
erolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res (2008)
49(11):2283–301. doi:10.1194/jlr.R800018-JLR200
77. Mittendorfer B. Origins of metabolic complications in obesity: adipose tis-
sue and free fatty acid trafﬁcking. Curr Opin Clin Nutr Metab Care (2011)
14(6):535–41. doi:10.1097/MCO.0b013e32834ad8b6
78. Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid con-
tent and insulin resistance: evidence for a paradox in endurance-trained
athletes. J Clin Endocrinol Metab (2001) 86(12):5755–61. doi:10.1210/jcem.86.
12.8075
79. LiuL,ShiX,BharadwajKG,IkedaS,YamashitaH,YagyuH,et al.DGAT1expres-
sionincreaseshearttriglyceridecontentbutameliorateslipotoxicity.JBiolChem
(2009) 284(52):36312–23. doi:10.1074/jbc.M109.049817
80. Benhamed F, Denechaud PD, Lemoine M, Robichon C, Moldes M, Bertrand-
Michel J, et al. The lipogenic transcription factor ChREBP dissociates hepatic
steatosis from insulin resistance in mice and humans. J Clin Invest (2012)
122(6):2176–94. doi:10.1172/JCI41636
81. Jiang T,Wang XX,Scherzer P,Wilson P,Tallman J,Takahashi H,et al. Farnesoid
Xreceptormodulatesrenallipidmetabolism,ﬁbrosis,anddiabeticnephropathy.
Diabetes (2007) 56(10):2485–93. doi:10.2337/db06-1642
82. Wang XX, Jiang T, Shen Y, Adorini L, Pruzanski M, Gonzalez FJ, et al. The far-
nesoid X receptor modulates renal lipid metabolism and diet-induced renal
inﬂammation, ﬁbrosis, and proteinuria. Am J Physiol Renal Physiol (2009)
297(6):F1587–96. doi:10.1152/ajprenal.00404.2009
ConﬂictofInterestStatement:Theauthorsdeclarethattheresearchwasconducted
in the absence of any commercial or ﬁnancial relationships that could be construed
as a potential conﬂict of interest.
Received: 24 August 2014; accepted: 13 October 2014; published online: 27 October
2014.
Citation:Sieber JandJehle AW(2014)Freefattyacidsandtheirmetabolismaffectfunc-
tionandsurvivalofpodocytes.Front.Endocrinol.5:186.doi:10.3389/fendo.2014.00186
This article was submitted to Cellular Endocrinology, a section of the journal Frontiers
in Endocrinology.
Copyright © 2014 Sieber and Jehle.This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
arecreditedandthattheoriginalpublicationinthisjournaliscited,inaccordancewith
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org October 2014 | Volume 5 | Article 186 | 7